Chemical risk assessment based on in vitro and human biomonitoring data: A case study on thyroid toxicants

Johansson, Hanna Katarina Lilith; Boberg, Julie; Dybdahl, Marianne; Axelstad, Marta; Vinggaard, Anne Marie

Published in:
Current Opinion in Toxicology

Link to article, DOI:
[10.1016/j.cotox.2018.12.001](https://doi.org/10.1016/j.cotox.2018.12.001)

Publication date:
2019

Document Version
Peer reviewed version

[Link back to DTU Orbit](#)

Citation (APA):
Johansson, H. K. L., Boberg, J., Dybdahl, M., Axelstad, M., & Vinggaard, A. M. (2019). Chemical risk assessment based on in vitro and human biomonitoring data: A case study on thyroid toxicants. *Current Opinion in Toxicology*, 15, 8-17. <https://doi.org/10.1016/j.cotox.2018.12.001>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

1 **Chemical risk assessment based on *in vitro* and human biomonitoring data: A**
2 **case study on thyroid toxicants**

3 Hanna KL Johansson, Julie Boberg, Marianne Dybdahl, Marta Axelstad, Anne Marie Vinggaard

4

5

6

7 **Affiliations:** *National Food Institute, Technical University of Denmark, Kemitorvet building 202, 2800 Kgs.*
8 *Lyngby, Denmark*

9 Corresponding author: *Anne Marie Vinggaard, annv@food.dtu.dk*

10

11

12

13

14

15

16 **Keywords:** Risk assessment, *in vitro*, human biomonitoring, thyroid toxicity, environmental
17 chemicals, PFOS

18

19

20 **Abstract**

21 Today detailed risk assessment can only be performed for a few percent of the total number of current-use
22 chemicals due to lack of data. Toxicity data is therefore needed for a substantial number of untested
23 chemicals, a task that requires improved and faster chemical risk assessment strategies that are cost-efficient,
24 human relevant and ethically responsible. In this commentary we use a case study on five known thyroid
25 toxic chemicals (perfluorooctanesulfonic acid (PFOS), triclosan, tetrabromobisphenol A (TBBPA),
26 decabromodiphenyl ether (BDE-209), and hexabromocyclododecane (HBCD)) to explore the use of *in vitro*
27 data for hazard assessment together with human biomonitoring (HBM) data for exposure assessment when
28 evaluating human risk. Based on the case study we conclude that *in vitro* and HBM data can be used for risk
29 ranking of chemicals. We envision that an *in vitro*/HBM approach can use data from studies such as the big
30 European initiative HBM4EU together with human relevant *in vitro* data to make alternative risk assessment
31 more valuable to finally be able to ‘stand-alone’.

32

33

34

35

36

37

38

39

40

1. Changing the paradigm for chemical risk assessment

Today we only have adequate information to perform detailed risk assessment for a few percent of the total number of current-use chemicals [1]. This reflects a considerable data gap, which is a bottleneck for prediction of human health effects caused by exposure to chemicals. We therefore need to gather or predict more toxicity and exposure data for a substantial number of untested chemicals, a task that – for many reasons – should not be solved by use of traditional animal-based methods only. Hence, improved and faster chemical risk assessment strategies are required to evaluate individual chemicals for which we need knowledge on human safety [2,3]. Here we propose a framework on how to risk rank chemicals based on *in vitro* data and human biomonitoring data (Fig. 1).

1.1 The current paradigm and challenges

Chemical hazard characterization is traditionally based on experimental animal data - often rodent data - for various organ toxicities, reproductive toxicity, carcinogenic effects and mutagenic effects [4]. While such data can be of great value there are several challenges, which complicates chemical risk assessments based solely on this information:

- A scientific challenge exists, as rodent studies do not always predict human responses. Comparison of human and rodent toxicity data for 150 pharmaceuticals showed that rodents predicted 43% of human responses [5].
- A practical challenge exists, as *in vivo* data is lacking for the majority of the industrial chemicals in current use [6].
- An ethical challenge exists, as based on the 3R principles [7], reductions on the use of animals for experimental toxicity studies should be made due to ethical reasons. This has resulted in political and

public pressure as well as EU legislation for test of cosmetics [8] where some *in vitro* approaches already exist.

Human exposure assessment of a specific chemical is often based on data derived separately for various relevant sources. For instance, exposure via food is often derived from data on chemical concentrations in various food items and average data for human food intake patterns, whereas exposure to the same chemical via cosmetics is assessed separately. Assessing aggregate exposures is thus a challenge [9,10] and still large data gaps exists on human exposure to chemicals [11]. Human internal exposure assessed via human biomonitoring (HBM) is a measure of aggregated exposure but are not routinely used in chemical risk assessment [12]. Yet HBM data is increasingly being gathered all over Europe (HBM4EU [13]) and US (NHANES [14]), presenting a great opportunity to evaluate human exposure across sources.

1.2 Towards a paradigm shift

A decade ago, the United States National Research Council presented a vision for chemical toxicity testing in the 21st century, in which computational biology and *in vitro* tests based on human biology play a central role [3]. Following this, high-throughput screening (HTS) programs such as ToxCast and Tox21 [2,15,16] were initiated. Such HTS systems, together with computational biology and “omics methods”, have generated data on hazard for large numbers of chemicals in a cost-efficient, human relevant and ethical way [2,17]. Several studies have been published on the use of HTS data in reverse dosimetry models for estimation of human exposure and ranking of chemicals [18–21]. In these studies, external intake dose was used as the measure of exposure, whereas we in the present study explore the use of HBM data as the measure of internal exposure. We argue that *in vitro* data for hazard assessment together with HBM data for exposure assessment has a future potential to accommodate some of the scientific, practical and ethical challenges we are presently facing. Our long-term vision is that the use of defined panels of *in vitro* tests combined with human HBM data for the chemical(s) in question can contribute significantly to chemical

87 regulation. For the purpose of this publication we present a case study with well-known thyroid toxic
88 chemicals.

89 **2. Case study on thyroid toxicants**

90 **2.1 Methodology**

91 We decided to focus on chemicals that disturb thyroid hormone levels as this is an emerging endocrine
92 mechanism of action for which new *in vitro* testing strategies are being developed. Our exercise was
93 hypothesized to highlight data gaps that might require future attention. Seventeen compounds were selected
94 for investigation based on their known thyroid toxic effect *in vivo* and relevant human exposure [12]. Out of
95 these seventeen, five were selected as model compounds based on relevance and available literature on *in*
96 *vitro* and HBM data; perfluorooctanesulfonic acid (PFOS), triclosan, tetrabromobisphenol A (TBBPA),
97 decabromodiphenyl ether (BDE-209), and hexabromocyclododecane (HBCD). A literature search was
98 conducted to extract HBM data (NHANES [22] and PubMed) and thyroid relevant *in vitro* data (PubMed
99 and ToxCast database [23]). For comparison we also included animal *in vivo* studies from which NOAELs
100 for thyroid effects were derived. To enable comparison across HBM, *in vitro* and *in vivo* studies, chemical
101 concentrations in human and animal blood was transformed to nM. The methodology is described in detail in
102 the Supplementary material, but in short: chemical blood levels from epidemiological and *in vivo* studies
103 were re-calculated from the unit g chemical/ g lipid or g chemical/ g wet weight of blood to nM. For triclosan
104 the calculation of human internal concentrations differed, as triclosan has a short half-life and is usually
105 measured in urine. Blood levels were therefore estimated by calculation of daily intake based on
106 concentrations found in urine [24] and hereafter a simplified one-compartment toxicokinetic model was
107 applied [25].

108 Risk characterization ratios (RCRs) were calculated for each chemical by division of the exposure estimate
109 based on HBM data with a reference value (RV) based on *in vitro* data ($RCR = \text{exposure}/RV$) [26]. The RCR
110 value reflects whether exposures exceed the concentrations considered “safe”. Thus, RCR values >1 indicate
111 that human exposure levels may be associated with a potential risk. RVs were based on *in vitro* data from
112 one experimental study for each chemical that was selected based on expert judgement in terms of relevance

113 of the mechanism of action and reliability of the study. . From the five selected *in vitro* studies, the ‘no
114 observed effect concentration’ (NOEC) value was used for RCR calculation. For chemicals with no reported
115 NOEC an extrapolation factor of 10 from LOEC to NOEC was used. Furthermore, we included studies in
116 zebrafish larvae for PFOS, TBBPA, and BDE-209, even though the larvae is not considered an *in vitro*
117 model, only the embryo is [27]. Studies considered to be potential outliers or not showing a mechanism
118 known to be thyroid specific, were excluded.

119 The *in vitro* studies included are presented in Table 1. The data shows a wide field of tested *in vitro* end
120 points with indications of effects on well-known thyroid endpoints such as antagonism of the thyroid
121 receptor (TR) [28] and transthyretin (TTR) binding [29] by PFOS, activation of the constitutive androstane
122 receptor (CAR) by a triclosan metabolite [30], TTR binding by TBBPA [31], TH reduction of BDE-209 in
123 zebrafish [32–34], as well as some thyroid-specific effect in hepatocytes by HBCD [35].

124 To take uncertainty of HBM data into account the exposure values were calculated based on an average of
125 means (PFOS, triclosan, TBBPA) or medians (BDE-209, HBCD). Exposure data with values below limit of
126 quantification/limit of detection, measurements in other matrices than blood or urine, studies from Asian
127 countries and occupational exposure studies, were excluded.

128

129 **2.2 Data availability**

130 Data on exposure and toxicity collected from HBM, *in vitro* and *in vivo* studies for the five chemicals are
131 depicted in Fig. 2 and the references used are shown in Table 1.

132 Due to limited resources, the HBM data included for PFOS and triclosan were limited to one representative
133 European study and data from the NHANES [22]. For TBBPA, BDE-209, and HBCD a thorough review of
134 the literature was conducted. For TBBPA, three HBM studies were included and several excluded due to
135 several studies with TBBPA levels below limit of quantification/limit of detection. For BDE-209, some
136 studies were also excluded due to measurements below the limit of detection/limit of quantification.
137 Exclusion of these data may somewhat skew the results, leading to an overestimation of the exposure for
138 these compounds.

139 The included *in vitro* studies have tested thyroid toxicity for a wide range of endpoints (Table 1), but not all
140 chemicals have been tested for all relevant mechanisms of thyroid toxicity. This approach, which includes a
141 range of assays, is analogous to classical risk assessment where several endpoints are evaluated and only the
142 most sensitive endpoint is used in the end.

143

144 **2.3 Output and ranking**

145 Ranking of the five compounds in terms of calculated RCR values based on *in vitro* NOEC values showed
146 that PFOS was associated with the highest risk (RCR = 8) and HBCD with the lowest (RCR=0.0001) (Table
147 2):

148

<i>PFOS</i> >> <i>TBBPA</i> > <i>BDE-209</i> > <i>Triclosan</i> > <i>HBCD</i>

150

151 Based on this analysis, exposure to PFOS alone is highlighted as a potential human health risk. The
152 association is of even greater concern considering that humans are exposed to several perfluorinated
153 compounds [36] that may have the same or similar mode(s) of action, which can cause cumulative effects.
154 The RCR ranking shows that PFOS needs further attention, although its use is restricted within the US [37]
155 and EU [38].

156 It should be noted, however, that the RCR values are subject to great uncertainties, both for the hazard and
157 exposure data. The RCR values presented here should therefore be regarded as indicative values suggested as
158 examples in this proposed framework, and not as values that should readily be used for risk assessment
159 purposes.

160 As can be seen in Fig. 2 the *in vitro* active concentrations and the blood levels at LOAELs and/or NOAELs
161 from animal experiments were not that different. However, for PFOS effects are seen at lower concentrations
162 *in vitro* than *in vivo*, whereas for triclosan the situation is opposite. This reflects that toxicity of some
163 perfluorinated chemicals generally seem to be underestimated by animal studies [39] and that human data
164 and physiologically-based kinetic modelling are needed for a proper risk assessment of this group of
165 chemicals. For triclosan the difference may be explained by species differences in CYP induction [40]. In

humans and rodents, increased liver catabolism of thyroid hormones has been identified as one of the primary modes of action of triclosan [40,41]. However, data from nuclear receptor reporter assays show that CAR and PXR activation by triclosan differs between the human and rodent [40], which indicates important species differences in thyroid hormone catabolism.

3. Future application of in vitro and biomonitoring data for risk assessment

3.1 A panel of human-based in vitro assays

We found limited relevant *in vitro* data and data that covers thyroid toxic mode(s) of action and/or key initiating events for the selected chemicals. Furthermore, there is a need for more human-based *in vitro* models as we in this case study only found a few assays based on human biology.

We suggest that defined panels of human-based *in vitro* assays are used to ensure that several important modes of action are covered, which is in line with the vision from the US National Research Council [3]. A defined panel of human-based *in vitro* assays would enable comparison and ranking of chemicals with different potencies, either by use of RCR values or a similar ratio. In terms of the practical challenge with thousands of untested chemicals on the market, *in vitro* assays enable high throughput test strategies such as the ToxCast and Tox21 initiatives in the US [2,15,16].

Toxicity is in some cases caused by metabolites and not the parent compound. The metabolic capacity of the *in vitro* system is therefore important to consider [42] and there are both extra- and intracellular options that can allow evaluation of metabolic capacity in the *in vitro* panel [43–45]. Furthermore, in order to obtain a quantitative link between HBM data and *in vitro* outputs - thereby improving predictions - it would be relevant to correct the *in vitro* output for factors such as protein binding, evaporation, binding to test plates/tubes/pipettes etc. in order to obtain the true intracellular concentration [46,47].

3.2 HBM data for exposure assessment

191 Use of HBM data for exposure assessment is a promising approach as it measures the sum of chemical
192 contributions from one or more routes of exposure as well as from different sources [48]. HBM data is also
193 valuable for assessment of chemicals with unknown or poorly characterized exposure pathways [49] and thus
194 the integrated internal exposure levels can be used as a better and more relevant measure [50]. Furthermore,
195 external exposure modelling, based on e.g. food consumption patterns and cosmetics use, is likely a greater
196 source of uncertainty than biological measurements [50,51]. On the other hand, HBM data cannot be
197 obtained for all compounds due to e.g. shared metabolites, and an important drawback is that it can only be
198 used for chemicals already on the market [48]. Evaluation of exposure based on HBM data will therefore
199 always be a retrospective rather than preventive approach. Furthermore, HBM data does not contribute with
200 information concerning timing and source of the exposure [48,52], which is central to chemical regulation.

201

202 ***3.3 Other examples of in vitro or HBM based risk assessment***

203 There are other examples of *in vitro* based risk assessment in the literature, however, many of these differ
204 from the present approach by use of external exposure dose (oral intake, mg/kg) [18–21,53], whereas we
205 have used internal exposure dose (blood concentration, nM) based on measured HBM data. Two examples
206 are Campell et al. [53] and Ring et al. [18]:

207 Campbell et al. [53], used *in vitro* based EC₁₀ values for estrogenic activity of parabens as surrogate “safe
208 exposure doses”. They used a Margin of Safety approach for risk assessment, which in essence is similar to
209 our approach, except that the inverse ratio was calculated, i.e. division of a no-effect level with an exposure
210 estimate.

211 Ring et al. [18] used data from ToxCast high-throughput *in vitro* screening assays applied for prioritization.
212 Bioactive *in vitro* concentrations were extrapolated to oral equivalent doses by reverse dosimetry, and these
213 doses were compared to external exposure doses calculated from HBM data. If the estimated exposure is
214 higher than the dose needed to obtain a bioactive concentration in blood, a potential risk is identified.
215 Interestingly, in that study triclosan was identified as one of the compounds with the smallest difference
216 between exposure and activity, i.e. as the most problematic and a priority for further evaluation [18].

217 HBM data have been applied in studies where their potential as exposure estimates has been investigated. A
218 comprehensive case study on benzene has been conducted [54], however, approaches more similar to the one
219 used in the present case study has been conducted by Hays et al. [51] and Aylward & Hays [50]. In both
220 these studies the authors concluded that internal dose measures from HBM studies are less uncertain than
221 estimated external doses in risk assessment.

222

223

224 **4. Conclusion**

225 We used a case study on five thyroid toxic compounds with differential mechanistic profiles to investigate
226 the potential use of human biomonitoring (HBM) together with *in vitro* data for informing human risk
227 assessment. We conclude that calculation of risk characterization ratios based on HBM and *in vitro* data is a
228 helpful tool for ranking chemicals and for designing follow-up studies.

229 The case study highlighted the pros and cons of informing the risk assessment process with *in vitro* and
230 HBM data and demonstrated that such data can be used for risk ranking of chemicals. Moreover, this
231 approach may be used for pinpointing chemicals for which species differences may play a major role,
232 thereby stressing the importance of basing the risk assessment on human-relevant data. Our vision is that an
233 *in vitro*/HBM approach can use the HBM4EU project - in parallel to the NHANES project in the US -
234 together with more comprehensive human relevant *in vitro* data to make ‘alternative’ risk assessment much
235 more valuable to finally be able to ‘stand-alone’.

236

237 **Acknowledgements**

238 We would like to thank Dr Terje Svingen for editorial input to the text. This work was financially supported
239 by the Ministry of Environment and Food of Denmark.

240 **Conflict of interest**

241 Declarations of interest: None.

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

Table 1: Case study literature overview for the five selected chemicals PFOS, triclosan, TBBPA, BDE-209 and HBCD. The first row shows the human biomonitoring (HBM) data with country of origin and references. The second row shows the *in vitro* data with endpoints measured, LOEC/EC_x values, the study used for calculation of risk characterization ratio (RCR) marked in bold, as well as references. The third row shows the *in vivo* data from animal experiments with endpoints and references.

	PFOS	Triclosan	TBBPA	BDE-209	HBCD
HBM data (country of origin)	US [22] Denmark [36]	US [22] Denmark [55]	France [56,57] Belgium [58]	US [59,60] UK [61–63] Greece [64] Spain [63,65–68] Netherlands [63] Germany [69] Denmark [70,71] Sweden [72–74] Norway [63]	Canada [75] Australia [76] Greece [64] Netherlands [77] Belgium [49,78] Germany [69] Sweden [79,80] Norway [81]
<i>In vitro</i> data (endpoints ranked according to potency. The study used for RCR calculation in bold)	Antagonism of TR LOEC 100 nM [28] Competitive binding to TTR IC ₅₀ 130 nM [29] T4 reduction and changed gene expression in zebrafish embryos LOEC 200 nM [82], LOEC 200 nM [83], LOEC 400 nM [84] Binding to TRα-LBD IC₅₀ 16000 nM [85] Inhibition of iodide uptake in hNIS assay LOEC 17000 nM [86]	Metabolite activated CAR EC₅₀ 900 nM [30], EC₅₀ 9800 nM [40] Inhibition of sulfotransferase IC₅₀ 1410 nM [87] Decreased NIS in FRTL-5 cells LOEC 10000 nM [88] Reduced activity of iodotyrosine deiodinase LOEC 60000 nM [89] TPO inhibition LOEC 253 000 nM [90]	TTR binding IC₅₀ 31 nM [31], IC₅₀ 3070 nM [91] Gene expression in zebra fish embryos LOEC 184 nM [92], LOEC 202 nM [93] Gene expression in zebra fish liver cells LOEC 400 nM [94] Growth hormone production in GH3 rat pituitary cells LOEC 1000 nM [95,96] Inhibition of rat disulfide isomerase IC₅₀ 1180 nM [97] TR antagonism and TR-related effects LOEC 1000 nM [98], LOEC 3000 nM [99], IC₅₀ 4600 nM [100], LOEC 10000 nM [101], IC₅₀ 29500 nM [102] TRα transcriptional regulation IC₇₅ 24000 nM [103] T-screen LOEC 10000 nM [104] Translocation of TRβ LOEC 25000 nM [105] Cell cycle regulation in human thyroid cells LOEC 75000 nM [106]	TH reduction, gene and protein expression in zebra fish embryos LOEC 83 nM [32], LOEC 83 nM [33] LOEC 104 nM [34] PXR activation LOEC 100000 nM [107]	Effects on TH-inducible hepatic protein and TTR in chicken embryonic hepatocytes LOEC 1000 nM [35] <i>Ex vivo Xenopus laevis</i> tadpole tail tip length regression LOEC 1000 nM [108] Increased TR-mediated gene expression LOEC 3120 nM [109] TTR binding IC₅₀ 12000 nM [31] T-screen LOEC 21000 nM [31]
<i>In vivo</i> animal data (endpoints)	Reduced T4 levels in monkeys at estimated blood concentrations of 26,000 nM (NOAEL) and 76,000 nM (LOAEL) [110,111]	Reduced T4 levels in rats at estimated blood concentrations of 21 nM (NOAEL) and 214 nM (LOAEL) [112,113]	Reduced thyroid hormone levels in rats at blood levels estimated to 919 nM (NOAEL) [114,115]	Reduced T4 in male rodents at blood levels estimated to 4800 nM (BMDL) [116–118]	Reduced T4 in female rats with a NOAEL of 200 µg/g lipid in liver [119]. According to Szabo et al. [120] HBCD blood levels are approximately 33% of the hepatic adipose tissue levels after 10 days of exposure in mice. Based on this the blood level was estimated to 395 nM (NOAEL)

261 **Table 2:** Human biomonitoring (HBM) data, *in vitro* data and calculated risk characterization ratios (RCRs) for the five chemicals
 262 (RCR = exposure (HBM data) /reference value (*in vitro*)).
 263

Data type	PFOS	Triclosan	TBBPA	BDE-209	HBOD
Human biomonitoring data Mean (nM)	25	0.04	0.2	0.05	0.01
In vitro data NOEC (nM)	3	90	3.1	8.3	100
Risk Characterization Ratio	8	0.0004	0.06	0.006	0.0001

264
 265
 266

267

268

269

Figure 1 . HBM data (green bars and dots), *in vitro* data (yellow bars and triangles), and *in vivo* data from animal experiments (blue triangles and squares) are depicted in this figure. The measured chemical levels in humans are generally lower than the effect concentrations found *in vitro* and *in vivo*. The exception is PFOS where the measured human levels and the effective concentrations *in vitro* are relatively close. Furthermore, average HBM values (orange, stippled lines) are relatively similar for all five chemicals except PFOS, where the internal human concentrations are higher. (LOEC = lowest observed effect concentration; ECx = Effect Concentration at X percent of effect; LOAEL = lowest observed adverse effect level, NOAEL = no observed adverse effect level; BMDL = bench mark dose level)

285 **References**

- 286 [1] United States Government Accountability Office, TOXIC SUBSTANCES: EPA Has Increased
287 Efforts to Assess and Control Chemicals but Could Strengthen Its Approach, Rep. to Congr.
288 Requesters. (2013) 49. <http://www.gao.gov/assets/660/653276.pdf>.
- 289 [2] F.S. Collins, G.M. Gray, J.R. Bucher, Transforming Environmental Health Protection, *Science* (80-.).
290 319 (2008) 906–907. doi:10.1126/science.1154619.
- 291 [3] National Research Council, Toxicity Testing in the 21st Century, National Academies Press,
292 Washington, D.C., 2007. doi:10.17226/11970.
- 293 [4] ECHA, Guidance on Information Requirements and Chemical Safety Assessment, (2011).
294 [https://echa.europa.eu/guidance-documents/guidance-on-information-requirements-and-chemical-](https://echa.europa.eu/guidance-documents/guidance-on-information-requirements-and-chemical-safety-assessment)
295 [safety-assessment](https://echa.europa.eu/guidance-documents/guidance-on-information-requirements-and-chemical-safety-assessment) (accessed July 3, 2018).
- 296 [5] H. Olson, G. Betton, D. Robinson, K. Thomas, A. Monro, G. Kolaja, P. Lilly, J. Sanders, G. Sipes,
297 W. Bracken, M. Dorato, K. Van Deun, P. Smith, B. Berger, A. Heller, Concordance of the Toxicity of
298 Pharmaceuticals in Humans and in Animals, *Regul. Toxicol. Pharmacol.* 32 (2000) 56–67.
299 doi:10.1006/rtph.2000.1399.
- 300 [6] A. Springer, H. Herrmann, D. Sittner, U. Herbst, A. Schulte, REACH Compliance: Data Availability
301 of REACH Registrations, Part 1: Screening of Chemicals > 1000 tpa, Berlin, 2015.
302 <https://www.umweltbundesamt.de/publikationen/reach-compliance-data-availability-of-reach>.
- 303 [7] B. Rusche, The 3Rs and animal welfare - conflict or the way forward?, *ALTEX Altern. Zu*
304 *Tierexperimenten*. 20 (2003) 63–76.
- 305 [8] European Parliament and the Council, Regulation (EC) No 1223/2009 on cosmetic products, (n.d.).
306 <https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:02009R1223-20160812>.
- 307 [9] D. Comiskey, A.M. Api, C. Barrett, G. Ellis, C. McNamara, C. O’Mahony, S.H. Robison, J. Rose, B.
308 Safford, B. Smith, S. Tozer, Integrating habits and practices data for soaps, cosmetics and air care
309 products into an existing aggregate exposure model, *Regul. Toxicol. Pharmacol.* 88 (2017) 144–156.
310 doi:10.1016/j.yrtph.2017.05.017.

- 311 [10] T.J. Lentz, G.S. Dotson, P.R.D. Williams, A. Maier, B. Gadagbui, S.P. Pandalai, A. Lamba, F. Hearl,
312 M. Mumtaz, Aggregate Exposure and Cumulative Risk Assessment—Integrating Occupational and
313 Non-occupational Risk Factors, *J. Occup. Environ. Hyg.* 12 (2015) S112–S126.
314 doi:10.1080/15459624.2015.1060326.
- 315 [11] P.P. Egeghy, R. Judson, S. Gangwal, S. Mosher, D. Smith, J. Vail, E.A. Cohen Hubal, The exposure
316 data landscape for manufactured chemicals, *Sci. Total Environ.* 414 (2012) 159–166.
317 doi:10.1016/j.scitotenv.2011.10.046.
- 318 [12] P.B. Larsen, J. Boberg, P.B. Poulsen, T.A. Mørck, H.B. Boyd, D.N. Andersen, M. Axelsted, U. Hass,
319 Exposure of children and unborn children to selected chemical substances, 2017.
320 <https://www2.mst.dk/Udgiv/publications/2017/04/978-87-93529-84-7.pdf>.
- 321 [13] HBM4EU, HBM4EU Sci. Policy a Heal. Futur. (n.d.). <https://www.hbm4eu.eu/> (accessed July 11,
322 2018).
- 323 [14] NHANES, NHANES. (n.d.). <https://www.cdc.gov/nchs/nhanes/index.htm> (accessed July 11, 2018).
- 324 [15] R.J. Kavlock, C.P. Austin, R.R. Tice, Toxicity Testing in the 21st Century: Implications for Human
325 Health Risk Assessment, *Risk Anal.* 29 (2009) 485–487. doi:10.1111/j.1539-6924.2008.01168.x.
- 326 [16] R. Kavlock, K. Chandler, K. Houck, S. Hunter, R. Judson, N. Kleinstreuer, T. Knudsen, M. Martin, S.
327 Padilla, D. Reif, A. Richard, D. Rotroff, N. Sipes, D. Dix, Update on EPA’s ToxCast Program:
328 Providing High Throughput Decision Support Tools for Chemical Risk Management, *Chem. Res.*
329 *Toxicol.* 25 (2012) 1287–1302. doi:10.1021/tx3000939.
- 330 [17] M.R. Gwinn, D.A. Axelrad, T. Bahadori, D. Bussard, W.E. Cascio, K. Deener, D. Dix, R.S. Thomas,
331 R.J. Kavlock, T.A. Burke, Chemical Risk Assessment: Traditional vs Public Health Perspectives,
332 *Am. J. Public Health.* 107 (2017) 1032–1039. doi:10.2105/AJPH.2017.303771.
- 333 [18] C.L. Ring, R.G. Pearce, R.W. Setzer, B.A. Wetmore, J.F. Wambaugh, Identifying populations
334 sensitive to environmental chemicals by simulating toxicokinetic variability, *Environ. Int.* 106 (2017)
335 105–118. doi:10.1016/j.envint.2017.06.004.
- 336 [19] N.S. Sipes, J.F. Wambaugh, R. Pearce, S.S. Auerbach, B.A. Wetmore, J.-H. Hsieh, A.J. Shapiro, D.
337 Svoboda, M.J. DeVito, S.S. Ferguson, An Intuitive Approach for Predicting Potential Human Health

338 Risk with the Tox21 10k Library, *Environ. Sci. Technol.* 51 (2017) 10786–10796.
 339 doi:10.1021/acs.est.7b00650.

340 [20] B.A. Wetmore, J.F. Wambaugh, B. Allen, S.S. Ferguson, M.A. Sochaski, R.W. Setzer, K.A. Houck,
 341 C.L. Strobe, K. Cantwell, R.S. Judson, E. LeCluyse, H.J. Clewell, R.S. Thomas, M.E. Andersen,
 342 Incorporating High-Throughput Exposure Predictions With Dosimetry-Adjusted In Vitro Bioactivity
 343 to Inform Chemical Toxicity Testing, *Toxicol. Sci.* 148 (2015) 121–136. doi:10.1093/toxsci/kfv171.

344 [21] B.A. Wetmore, J.F. Wambaugh, S.S. Ferguson, M.A. Sochaski, D.M. Rotroff, K. Freeman, H.J.
 345 Clewell, D.J. Dix, M.E. Andersen, K.A. Houck, B. Allen, R.S. Judson, R. Singh, R.J. Kavlock, A.M.
 346 Richard, R.S. Thomas, Integration of Dosimetry, Exposure, and High-Throughput Screening Data in
 347 Chemical Toxicity Assessment, *Toxicol. Sci.* 125 (2012) 157–174. doi:10.1093/toxsci/kfr254.

348 [22] NHANES, Fourth National Report on Human Exposure to Environmental Chemicals, Department of
 349 Health and Human Services Centers for Disease Control and Prevention, 2009.
 350 <http://www.cdc.gov/exposurereport/pdf/fourthreport.pdf>.

351 [23] U. EPA, ToxCast, (n.d.). <https://actor.epa.gov/dashboard/>.

352 [24] H.M. Koch, K. Becker, M. Wittassek, M. Seiwert, J. Angerer, M. Kolossa-Gehring, Di-n-
 353 butylphthalate and butylbenzylphthalate — urinary metabolite levels and estimated daily intakes:
 354 pilot study for the German Environmental Survey on children, *J. Expo. Sci. Environ. Epidemiol.* 17
 355 (2007) 378–387. doi:10.1038/sj.jes.7500526.

356 [25] H. Fromme, M. Schlummer, A. Möller, L. Gruber, G. Wolz, J. Ungewiss, S. Böhmer, W. Dekant, R.
 357 Mayer, B. Liebl, D. Twardella, Exposure of an Adult Population to Perfluorinated Substances Using
 358 Duplicate Diet Portions and Biomonitoring Data, *Environ. Sci. Technol.* 41 (2007) 7928–7933.
 359 doi:10.1021/es071244n.

360 [26] ECHA, Guidance on Information Requirements and Chemical Safety Assessment - Part E: Risk
 361 Characterisation, 2016.
 362 http://echa.europa.eu/documents/10162/13632/information_requirements_r11_en.pdf.

363 [27] OECD, OECD guidelines for the testing of chemicals. Fish embryo acute toxicity (FET) test. TG 236,
 364 2013. doi:10.1787/9789264067332-en.

- [28] G. Du, J. Hu, H. Huang, Y. Qin, X. Han, D. Wu, L. Song, Y. Xia, X. Wang, Perfluorooctane sulfonate (PFOS) affects hormone receptor activity, steroidogenesis, and expression of endocrine-related genes in vitro and in vivo, *Environ. Toxicol. Chem.* 32 (2013) 353–360. doi:10.1002/etc.2034.
- [29] X.-M. Ren, W.-P. Qin, L.-Y. Cao, J. Zhang, Y. Yang, B. Wan, L.-H. Guo, Binding interactions of perfluoroalkyl substances with thyroid hormone transport proteins and potential toxicological implications, *Toxicology*. 366–367 (2016) 32–42. doi:10.1016/j.tox.2016.08.011.
- [30] P. Ashrap, G. Zheng, Y. Wan, T. Li, W. Hu, W. Li, H. Zhang, Z. Zhang, J. Hu, Discovery of a widespread metabolic pathway within and among phenolic xenobiotics, *Proc. Natl. Acad. Sci.* 114 (2017) 6062–6067. doi:10.1073/pnas.1700558114.
- [31] T. Hamers, J.H. Kamstra, E. Sonneveld, A.J. Murk, M.H.A. Kester, P.L. Andersson, J. Legler, A. Brouwer, In Vitro Profiling of the Endocrine-Disrupting Potency of Brominated Flame Retardants, *Toxicol. Sci.* 92 (2006) 157–173. doi:10.1093/toxsci/kfj187.
- [32] Q. Chen, L. Yu, L. Yang, B. Zhou, Bioconcentration and metabolism of decabromodiphenyl ether (BDE-209) result in thyroid endocrine disruption in zebrafish larvae, *Aquat. Toxicol.* 110–111 (2012) 141–148. doi:10.1016/j.aquatox.2012.01.008.
- [33] Q. Wang, Q. Chen, P. Zhou, W. Li, J. Wang, C. Huang, X. Wang, K. Lin, B. Zhou, Bioconcentration and metabolism of BDE-209 in the presence of titanium dioxide nanoparticles and impact on the thyroid endocrine system and neuronal development in zebrafish larvae, *Nanotoxicology*. 8 (2014) 196–207. doi:10.3109/17435390.2013.875232.
- [34] B. Zhu, Q. Wang, X. Wang, B. Zhou, Impact of co-exposure with lead and decabromodiphenyl ether (BDE-209) on thyroid function in zebrafish larvae, *Aquat. Toxicol.* 157 (2014) 186–195. doi:10.1016/j.aquatox.2014.10.011.
- [35] D. Crump, S. Chiu, C. Egloff, S.W. Kennedy, Effects of Hexabromocyclododecane and Polybrominated Diphenyl Ethers on mRNA Expression in Chicken (*Gallus domesticus*) Hepatocytes, *Toxicol. Sci.* 106 (2008) 479–487. doi:10.1093/toxsci/kfn196.
- [36] T.A. Mørck, F. Nielsen, J.K.S. Nielsen, V.D. Siersma, P. Grandjean, L.E. Knudsen, PFAS concentrations in plasma samples from Danish school children and their mothers, *Chemosphere*. 129

- (2015) 203–209. doi:10.1016/j.chemosphere.2014.07.018.
- [37] US EPA, PFAS Laws and Regulations, United States Environ. Prot. Agency. (2018).
<https://www.epa.gov/pfas/pfas-laws-and-regulations> (accessed August 16, 2018).
- [38] ChemSafetyPRO, Perfluorooctane sulfonic acid and its derivatives (PFOS), PFOS Restriction limits in EU, ChemSafetyPRO. (2018).
http://www.chemsafetypro.com/Topics/Restriction/PFOS_EU_restriction_limit_PFOS_and_REACH_annex_XVII.html (accessed August 16, 2018).
- [39] ECHA, ANNEX XV Restriction report proposal for a restriction. Perfluorooctanoic acid (PFOA), PFOA salts and PFOA-related substances, Version 1. (2014) 1–155.
<https://echa.europa.eu/documents/10162/e9cddee6-3164-473d-b590-8fcf9caa50e7>.
- [40] K.B. Paul, J.T. Thompson, S.O. Simmons, J.P. Vanden Heuvel, K.M. Crofton, Evidence for triclosan-induced activation of human and rodent xenobiotic nuclear receptors, *Toxicol. Vitro*. 27 (2013) 2049–2060. doi:10.1016/j.tiv.2013.07.008.
- [41] N. Hanioka, H. Jinno, T. Nishimura, M. Ando, Effect of 2,4,4'-trichloro-2'-hydroxydiphenyl ether on cytochrome P450 enzymes in the rat liver, *Chemosphere*. 34 (1997) 719–30.
<http://www.ncbi.nlm.nih.gov/pubmed/9569940>.
- [42] B.J. Blaauboer, The necessity of biokinetic information in the interpretation of in vitro toxicity data, *ATLA Altern. to Lab. Anim*. 30 (2002) 85–91.
- [43] D.E. DeGroot, A. Swank, R.S. Thomas, M. Strynar, M.-Y. Lee, P.L. Carmichael, S.O. Simmons, mRNA transfection retrofits cell-based assays with xenobiotic metabolism, *J. Pharmacol. Toxicol. Methods*. 92 (2018) 77–94. doi:10.1016/j.vascn.2018.03.002.
- [44] M.T. Donato, A. Lahoz, J.V. Castell, M.J. Gomez-Lechon, Cell Lines: A Tool for In Vitro Drug Metabolism Studies, *Curr. Drug Metab.* 9 (2008) 1–11. doi:10.2174/138920008783331086.
- [45] J. Mollergues, B. van Vugt-Lussenburg, C. Kirchnawy, R.A. Bandi, R.B. van der Lee, M. Marin-Kuan, B. Schilter, K.C. Fussell, Incorporation of a metabolizing system in biodetection assays for endocrine active substances, *ALTEX*. 34 (2017) 389–398. doi:10.14573/altex.1611021.
- [46] D. Gilbert, P. Mayer, M. Pedersen, A.M. Vinggaard, Endocrine activity of persistent organic

- pollutants accumulated in human silicone implants — Dosing in vitro assays by partitioning from silicone, *Environ. Int.* 84 (2015) 107–114. doi:10.1016/j.envint.2015.07.008.
- [47] Z. Dong, Y. Liu, L. Duan, D. Bekele, R. Naidu, Uncertainties in human health risk assessment of environmental contaminants: A review and perspective, *Environ. Int.* 85 (2015) 120–132. doi:10.1016/j.envint.2015.09.008.
- [48] P.J. Liroy, Exposure science: A view of the past and milestones for the future, *Environ. Health Perspect.* 118 (2010) 1081–1090. doi:10.1289/ehp.0901634.
- [49] L. Roosens, M. Abdallah, S. Harrad, H. Neels, A. Covaci, Exposure to Hexabromocyclododecanes (HBCDs) via Dust Ingestion, but not Diet, Correlates with Concentrations in Human Serum - Preliminary Results, *Environ. Health Perspect.* 117 (2009) 1707–1712. doi:10.1289/ehp.0900869.
- [50] L.L. Aylward, S.M. Hays, Biomonitoring-based risk assessment for hexabromocyclododecane (HBCD), *Int. J. Hyg. Environ. Health.* 214 (2011) 179–187. doi:10.1016/j.ijheh.2011.02.002.
- [51] S.M. Hays, L.L. Aylward, J. Driver, J. Ross, C. Kirman, 2,4-D Exposure and risk assessment: Comparison of external dose and biomonitoring based approaches, *Regul. Toxicol. Pharmacol.* 64 (2012) 481–489. doi:10.1016/j.yrtph.2012.09.001.
- [52] A.M. Calafat, Contemporary Issues in Exposure Assessment Using Biomonitoring, *Curr. Epidemiol. Reports.* 3 (2016) 145–153. doi:10.1007/s40471-016-0075-7.
- [53] J.L. Campbell, M. Yoon, H.J. Clewell, A case study on quantitative in vitro to in vivo extrapolation for environmental esters: Methyl-, propyl- and butylparaben, *Toxicology.* 332 (2015) 67–76. doi:10.1016/j.tox.2015.03.010.
- [54] S.M. Arnold, J. Angerer, P.J. Boogaard, M.F. Hughes, R.B. O’Lone, S.H. Robison, A. Robert Schnatter, The use of biomonitoring data in exposure and human health risk assessment: benzene case study, *Crit. Rev. Toxicol.* 43 (2013) 119–153. doi:10.3109/10408444.2012.756455.
- [55] H. Frederiksen, T.K. Jensen, N. Jorgensen, H.B. Kyhl, S. Husby, N.E. Skakkebaek, K.M. Main, A. Juul, A.-M. Andersson, Human urinary excretion of non-persistent environmental chemicals: an overview of Danish data collected between 2006 and 2012, *Reproduction.* 147 (2014) 555–565. doi:10.1530/REP-13-0522.

- 446 [56] J.-P. Antignac, R. Cariou, D. Maume, P. Marchand, F. Monteau, D. Zalko, A. Berrebi, J.-P. Cravedi,
447 F. Andre, B. Le Bizec, Exposure assessment of fetus and newborn to brominated flame retardants in
448 France: preliminary data, *Mol. Nutr. Food Res.* 52 (2008) 258–265. doi:10.1002/mnfr.200700077.
- 449 [57] R. Cariou, J.-P. Antignac, D. Zalko, A. Berrebi, J.-P. Cravedi, D. Maume, P. Marchand, F. Monteau,
450 A. Riu, F. Andre, B. Le Bizec, Exposure assessment of French women and their newborns to
451 tetrabromobisphenol-A: Occurrence measurements in maternal adipose tissue, serum, breast milk and
452 cord serum, *Chemosphere.* 73 (2008) 1036–1041. doi:10.1016/j.chemosphere.2008.07.084.
- 453 [58] A.C. Dirtu, L. Roosens, T. Geens, A. Gheorghe, H. Neels, A. Covaci, Simultaneous determination of
454 bisphenol A, triclosan, and tetrabromobisphenol A in human serum using solid-phase extraction and
455 gas chromatography-electron capture negative-ionization mass spectrometry, *Anal. Bioanal. Chem.*
456 391 (2008) 1175–1181. doi:10.1007/s00216-007-1807-9.
- 457 [59] S. Lunder, L. Hovander, I. Athanassiadis, Å. Bergman, Significantly Higher Polybrominated
458 Diphenyl Ether Levels in Young U.S. Children than in Their Mothers, *Environ. Sci. Technol.* 44
459 (2010) 5256–5262. doi:10.1021/es1009357.
- 460 [60] A. Sjödin, D.G. Patterson, Å. Bergman, Brominated Flame Retardants in Serum from U.S. Blood
461 Donors, *Environ. Sci. Technol.* 35 (2001) 3830–3833. doi:10.1021/es010815n.
- 462 [61] L. Bramwell, A. Fernandes, M. Rose, S. Harrad, T. Pless-Mulloli, PBDEs and PBBs in human serum
463 and breast milk from cohabiting UK couples, *Chemosphere.* 116 (2014) 67–74.
464 doi:10.1016/j.chemosphere.2014.03.060.
- 465 [62] G.O. Thomas, M. Wilkinson, S. Hodson, K.C. Jones, Organohalogen chemicals in human blood from
466 the United Kingdom, *Environ. Pollut.* 141 (2006) 30–41. doi:10.1016/j.envpol.2005.08.027.
- 467 [63] M. van den Berg, R. Houba, H.A. Leslie, R.F. Canton, C. Thomsen, G. Becher, M. Alvarez-Pedrerol,
468 J.S. Deu, M. Steiner, M. van Tongeren, B. Brunekreef, J. de Boer, Serum levels of
469 decabromodiphenyl ether (BDE-209) in women from different European countries and possible
470 relationships with lifestyle and diet, *Environ. Int.* 107 (2017) 16–24.
471 doi:10.1016/j.envint.2017.06.014.
- 472 [64] O.I. Kalantzi, T. Geens, A. Covaci, P.A. Siskos, Distribution of polybrominated diphenyl ethers

- (PBDEs) and other persistent organic pollutants in human serum from Greece, *Environ. Int.* 37 (2011) 349–353. doi:10.1016/j.envint.2010.10.005.
- [65] B. Gómara, L. Herrero, J.J. Ramos, J.R. Mateo, M.A. Fernández, J.F. García, M.J. González, Distribution of Polybrominated Diphenyl Ethers in Human Umbilical Cord Serum, Paternal Serum, Maternal Serum, Placentas, and Breast Milk from Madrid Population, Spain, *Environ. Sci. Technol.* 41 (2007) 6961–6968. doi:10.1021/es0714484.
- [66] M. Garí, J.O. Grimalt, Inverse age-dependent accumulation of decabromodiphenyl ether and other PBDEs in serum from a general adult population, *Environ. Int.* 54 (2013) 119–127. doi:10.1016/j.envint.2013.01.012.
- [67] E. Vizcaino, J.O. Grimalt, A. Fernández-Somoano, A. Tardon, Transport of persistent organic pollutants across the human placenta, *Environ. Int.* 65 (2014) 107–115. doi:10.1016/j.envint.2014.01.004.
- [68] E. Vizcaino, J.O. Grimalt, M.-J. Lopez-Espinosa, S. Llop, M. Rebagliato, F. Ballester, Polybromodiphenyl ethers in mothers and their newborns from a non-occupationally exposed population (Valencia, Spain), *Environ. Int.* 37 (2011) 152–157. doi:10.1016/j.envint.2010.08.011.
- [69] H. Fromme, B. Hilger, M. Albrecht, W. Gries, G. Leng, W. Völkel, Occurrence of chlorinated and brominated dioxins/furans, PCBs, and brominated flame retardants in blood of German adults., *Int. J. Hyg. Environ. Health.* 219 (2016) 380–388. doi:10.1016/j.ijheh.2016.03.003.
- [70] K. Vorkamp, F. Nielsen, H.B. Kyhl, S. Husby, L.B. Nielsen, T. Barington, A.-M. Andersson, T.K. Jensen, Polybrominated Diphenyl Ethers and Perfluoroalkyl Substances in Serum of Pregnant Women: Levels, Correlations, and Potential Health Implications, *Arch. Environ. Contam. Toxicol.* 67 (2014) 9–20. doi:10.1007/s00244-013-9988-z.
- [71] M. Frederiksen, C. Thomsen, M. Frøshaug, K. Vorkamp, M. Thomsen, G. Becher, L.E. Knudsen, Polybrominated diphenyl ethers in paired samples of maternal and umbilical cord blood plasma and associations with house dust in a Danish cohort, *Int. J. Hyg. Environ. Health.* 213 (2010) 233–242. doi:10.1016/j.ijheh.2010.04.008.
- [72] L.M.O. Sahlström, U. Sellström, C.A. de Wit, S. Lignell, P.O. Darnerud, Brominated Flame

Retardants in Matched Serum Samples from Swedish First-Time Mothers and Their Toddlers, Environ. Sci. Technol. 48 (2014) 7584–7592. doi:10.1021/es501139d.

[73] H. Bjermo, M. Aune, T. Cantillana, A. Glynn, P.M. Lind, P. Ridefelt, P.O. Darnerud, Serum levels of brominated flame retardants (BFRs: PBDE, HBCD) and influence of dietary factors in a population-based study on Swedish adults, Chemosphere. 167 (2017) 485–491. doi:10.1016/j.chemosphere.2016.10.008.

[74] K. Jakobsson, J. Fång, M. Athanasiadou, A. Rignell-Hydbom, Å. Bergman, Polybrominated diphenyl ethers in maternal serum, umbilical cord serum, colostrum and mature breast milk. Insights from a pilot study and the literature, Environ. Int. 47 (2012) 121–130. doi:10.1016/j.envint.2012.05.006.

[75] D.F.K. Rawn, J.J. Ryan, A.R. Sadler, W.-F. Sun, D. Weber, P. Laffey, D. Haines, K. Macey, J. Van Oostdam, Brominated flame retardant concentrations in sera from the Canadian Health Measures Survey (CHMS) from 2007 to 2009, Environ. Int. 63 (2014) 26–34. doi:10.1016/j.envint.2012.05.008.

[76] D.S. Drage, J.F. Mueller, P. Hobson, F.A. Harden, L.-M.L. Toms, Demographic and temporal trends of hexabromocyclododecanes (HBCDD) in an Australian population, Environ. Res. 152 (2017) 192–198. doi:10.1016/j.envres.2016.10.015.

[77] L. Meijer, J. Weiss, M. van Velzen, A. Brouwer, Å. Bergman, P.J.J. Sauer, Serum Concentrations of Neutral and Phenolic Organohalogens in Pregnant Women and Some of Their Infants in The Netherlands, Environ. Sci. Technol. 42 (2008) 3428–3433. doi:10.1021/es702446p.

[78] M. Kiciński, M.K. Viaene, E. Den Hond, G. Schoeters, A. Covaci, A.C. Dirtu, V. Nelen, L. Bruckers, K. Croes, I. Sioen, W. Baeyens, N. Van Larebeke, T.S. Nawrot, Neurobehavioral function and low-level exposure to brominated flame retardants in adolescents: a cross-sectional study, Environ. Heal. 11 (2012) 86. doi:10.1186/1476-069X-11-86.

[79] P.O. Darnerud, S. Lignell, M. Aune, M. Isaksson, T. Cantillana, J. Redebý, A. Glynn, Time trends of polybrominated diphenylether (PBDE) congeners in serum of Swedish mothers and comparisons to breast milk data, Environ. Res. 138 (2015) 352–360. doi:10.1016/j.envres.2015.02.031.

[80] J. Weiss, E. Wallin, A. Axmon, B.A.G. Jönsson, H. Åkesson, K. Janák, L. Hagmar, Å. Bergman,

527 Hydroxy-PCBs, PBDEs, and HBCDDs in Serum from an Elderly Population of Swedish Fishermen's
 528 Wives and Associations with Bone Density, *Environ. Sci. Technol.* 40 (2006) 6282–6289.
 529 doi:10.1021/es0610941.

530 [81] C. Thomsen, H.K. Knutsen, V.H. Liane, M. Frøshaug, H.E. Kvale, M. Haugen, H.M. Meltzer, J.
 531 Alexander, G. Becher, Consumption of fish from a contaminated lake strongly affects the
 532 concentrations of polybrominated diphenyl ethers and hexabromocyclododecane in serum, *Mol. Nutr.*
 533 *Food Res.* 52 (2008) 228–237. doi:10.1002/mnfr.200700123.

534 [82] X. Shi, Y. Du, P.K.S. Lam, R.S.S. Wu, B. Zhou, Developmental toxicity and alteration of gene
 535 expression in zebrafish embryos exposed to PFOS, *Toxicol. Appl. Pharmacol.* 230 (2008) 23–32.
 536 doi:10.1016/j.taap.2008.01.043.

537 [83] X. Shi, C. Liu, G. Wu, B. Zhou, Waterborne exposure to PFOS causes disruption of the
 538 hypothalamus–pituitary–thyroid axis in zebrafish larvae, *Chemosphere.* 77 (2009) 1010–1018.
 539 doi:10.1016/j.chemosphere.2009.07.074.

540 [84] J. Du, S. Wang, H. You, Z. Liu, Effects of ZnO nanoparticles on perfluorooctane sulfonate induced
 541 thyroid-disrupting on zebrafish larvae, *J. Environ. Sci.* 47 (2016) 153–164.
 542 doi:10.1016/j.jes.2016.01.018.

543 [85] X.-M. Ren, Y.-F. Zhang, L.-H. Guo, Z.-F. Qin, Q.-Y. Lv, L.-Y. Zhang, Structure–activity relations in
 544 binding of perfluoroalkyl compounds to human thyroid hormone T3 receptor, *Arch. Toxicol.* 89
 545 (2015) 233–242. doi:10.1007/s00204-014-1258-y.

546 [86] J. Wang, D.R. Hallinger, A.S. Murr, A.R. Buckalew, S.O. Simmons, S.C. Laws, T.E. Stoker, High-
 547 Throughput Screening and Quantitative Chemical Ranking for Sodium-Iodide Symporter Inhibitors in
 548 ToxCast Phase I Chemical Library, *Environ. Sci. Technol.* 52 (2018) 5417–5426.
 549 doi:10.1021/acs.est.7b06145.

550 [87] C.M. Butt, H.M. Stapleton, Inhibition of Thyroid Hormone Sulfotransferase Activity by Brominated
 551 Flame Retardants and Halogenated Phenolics, *Chem. Res. Toxicol.* 26 (2013) 1692–1702.
 552 doi:10.1021/tx400342k.

553 [88] Y. Wu, F.A. Beland, J.-L. Fang, Effect of triclosan, triclocarban, 2,2',4,4'-tetrabromodiphenyl ether,

554 and bisphenol A on the iodide uptake, thyroid peroxidase activity, and expression of genes involved
 555 in thyroid hormone synthesis, *Toxicol. Vitro.* 32 (2016) 310–319. doi:10.1016/j.tiv.2016.01.014.

556 [89] R. Shimizu, M. Yamaguchi, N. Uramaru, H. Kuroki, S. Ohta, S. Kitamura, K. Sugihara, Structure–
 557 activity relationships of 44 halogenated compounds for iodotyrosine deiodinase-inhibitory activity,
 558 *Toxicology.* 314 (2013) 22–29. doi:10.1016/j.tox.2013.08.017.

559 [90] K.B. Paul, J.M. Hedge, D.M. Rotroff, M.W. Hornung, K.M. Crofton, S.O. Simmons, Development of
 560 a Thyroperoxidase Inhibition Assay for High-Throughput Screening, *Chem. Res. Toxicol.* 27 (2014)
 561 387–399. doi:10.1021/tx400310w.

562 [91] Y. Kudo, K. Yamauchi, H. Fukazawa, Y. Terao, In Vitro and In Vivo Analysis of the Thyroid
 563 System–Disrupting Activities of Brominated Phenolic and Phenol Compounds in *Xenopus laevis*,
 564 *Toxicol. Sci.* 92 (2006) 87–95. doi:10.1093/toxsci/kfj204.

565 [92] L. Baumann, A. Ros, K. Rehberger, S.C.F. Neuhauss, H. Segner, Thyroid disruption in zebrafish
 566 (*Danio rerio*) larvae: Different molecular response patterns lead to impaired eye development and
 567 visual functions, *Aquat. Toxicol.* 172 (2016) 44–55. doi:10.1016/j.aquatox.2015.12.015.

568 [93] W.K. Chan, K.M. Chan, Disruption of the hypothalamic-pituitary-thyroid axis in zebrafish embryo–
 569 larvae following waterborne exposure to BDE-47, TBBPA and BPA, *Aquat. Toxicol.* 108 (2012)
 570 106–111. doi:10.1016/j.aquatox.2011.10.013.

571 [94] J. Yang, K.M. Chan, Evaluation of the toxic effects of brominated compounds (BDE-47, 99, 209,
 572 TBBPA) and bisphenol A (BPA) using a zebrafish liver cell line, ZFL, *Aquat. Toxicol.* 159 (2015)
 573 138–147. doi:10.1016/j.aquatox.2014.12.011.

574 [95] S. Kitamura, N. Jinno, S. Ohta, H. Kuroki, N. Fujimoto, Thyroid hormonal activity of the flame
 575 retardants tetrabromobisphenol A and tetrachlorobisphenol A, *Biochem. Biophys. Res. Commun.* 293
 576 (2002) 554–559. doi:10.1016/S0006-291X(02)00262-0.

577 [96] S. Kitamura, T. Suzuki, S. Sanoh, R. Kohta, N. Jinno, K. Sugihara, S. Yoshihara, N. Fujimoto, H.
 578 Watanabe, S. Ohta, Comparative Study of the Endocrine-Disrupting Activity of Bisphenol A and 19
 579 Related Compounds, *Toxicol. Sci.* 84 (2005) 249–259. doi:10.1093/toxsci/kfi074.

580 [97] K. Okada, T. Hiroi, S. Imaoka, Y. Funae, Inhibitory effects of environmental chemicals on protein

581 disulfide isomerase in vitro., Osaka City Med. J. 51 (2005) 51–63.
582 <http://www.ncbi.nlm.nih.gov/pubmed/16617682>.

583 [98] S. Otsuka, A. Ishihara, K. Yamauchi, Ioxynil and Tetrabromobisphenol A Suppress Thyroid-
584 Hormone-Induced Activation of Transcriptional Elongation Mediated by Histone Modifications and
585 RNA Polymerase II Phosphorylation, Toxicol. Sci. 138 (2014) 290–299. doi:10.1093/toxsci/kfu012.

586 [99] J.B. Fini, A. Riu, L. Debrauwer, A. Hillenweck, S. Le mével, S. Chevolleau, A. Boulahtouf, K.
587 Palmier, P. Balaguer, J.P. Cravedi, B.A. Demeneix, D. Zalko, Parallel biotransformation of
588 tetrabromobisphenol A in *Xenopus laevis* and mammals: *Xenopus* as a model for endocrine
589 perturbation studies, Toxicol. Sci. 125 (2012) 359–367. doi:10.1093/toxsci/kfr312.

590 [100] M. Terasaki, K. Kosaka, S. Kunikane, M. Makino, F. Shiraishi, Assessment of thyroid hormone
591 activity of halogenated bisphenol A using a yeast two-hybrid assay, Chemosphere. 84 (2011) 1527–
592 1530. doi:10.1016/j.chemosphere.2011.04.045.

593 [101] M.L. Jugan, M. Lévy-Bimbot, M. Pomérance, S. Tamisier-Karolak, J.P. Blondeau, Y. Lévi, A new
594 bioluminescent cellular assay to measure the transcriptional effects of chemicals that modulate the
595 alpha-1 thyroid hormone receptor, Toxicol. Vit. 21 (2007) 1197–1205.
596 doi:10.1016/j.tiv.2007.03.020.

597 [102] H. Sun, O.-X. Shen, X.-R. Wang, L. Zhou, S. Zhen, X. Chen, Anti-thyroid hormone activity of
598 bisphenol A, tetrabromobisphenol A and tetrachlorobisphenol A in an improved reporter gene assay,
599 Toxicol. Vit. 23 (2009) 950–954. doi:10.1016/j.tiv.2009.05.004.

600 [103] M. Lévy-Bimbot, G. Major, D. Courilleau, J.-P. Blondeau, Y. Lévi, Tetrabromobisphenol-A disrupts
601 thyroid hormone receptor alpha function in vitro: Use of fluorescence polarization to assay
602 corepressor and coactivator peptide binding, Chemosphere. 87 (2012) 782–788.
603 doi:10.1016/j.chemosphere.2011.12.080.

604 [104] M. Ghisari, E.C. Bonefeld-Jorgensen, Impact of environmental chemicals on the thyroid hormone
605 function in pituitary rat GH3 cells, Mol. Cell. Endocrinol. 244 (2005) 31–41.
606 doi:10.1016/j.mce.2005.01.013.

607 [105] D.A. Stavreva, L. Varticovski, L. Levkova, A.A. George, L. Davis, G. Pegoraro, V. Blazer, L.

608 Iwanowicz, G.L. Hager, Novel cell-based assay for detection of thyroid receptor beta-interacting
609 environmental contaminants, *Toxicology*. 368–369 (2016) 69–79. doi:10.1016/j.tox.2016.08.012.

610 [106] S. Strack, T. Detzel, M. Wahl, B. Kuch, H.F. Krug, Cytotoxicity of TBBPA and effects on
611 proliferation, cell cycle and MAPK pathways in mammalian cells, *Chemosphere*. 67 (2007) S405–
612 S411. doi:10.1016/j.chemosphere.2006.05.136.

613 [107] E.K. Pacyniak, X. Cheng, M.L. Cunningham, K. Crofton, C.D. Klaassen, G.L. Guo, The Flame
614 Retardants, Polybrominated Diphenyl Ethers, Are Pregnane X Receptor Activators, *Toxicol. Sci.* 97
615 (2007) 94–102. doi:10.1093/toxsci/kfm025.

616 [108] M. Schriks, E. Zvinavashe, J. David Furlow, A.J. Murk, Disruption of thyroid hormone-mediated
617 *Xenopus laevis* tadpole tail tip regression by hexabromocyclododecane (HBCD) and
618 2,2',3,3',4,4',5,5',6-nona brominated diphenyl ether (BDE206), *Chemosphere*. 65 (2006) 1904–1908.
619 doi:10.1016/j.chemosphere.2006.07.077.

620 [109] T. Yamada-Okabe, H. Sakai, Y. Kashima, H. Yamada-Okabe, Modulation at a cellular level of the
621 thyroid hormone receptor-mediated gene expression by 1,2,5,6,9,10-hexabromocyclododecane
622 (HBCD), 4,4'-diiodobiphenyl (DIB), and nitrofen (NIP), *Toxicol. Lett.* 155 (2005) 127–133.
623 doi:10.1016/j.toxlet.2004.09.005.

624 [110] EFSA, Perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA) and their salts - Scientific
625 opinion of the Panel on Contaminants in the Food chain, *EFSA J.* 653 (2008) 1–131.
626 doi:10.2903/j.efsa.2008.653.

627 [111] A.M. Seacat, P.J. Thomford, K.J. Hansen, L.A. Clemen, S.R. Eldridge, C.R. Elcombe, J.L. Butenhoff,
628 Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats, *Toxicology*. 183 (2003)
629 117–131. doi:10.1016/S0300-483X(02)00511-5.

630 [112] SCCP, OPINION ON TRICLOSAN, *Sci. Comm. Consum. Prod. SCCP.* (2009). doi:10.2772/96027.

631 [113] L.M. Zorrilla, E.K. Gibson, S.C. Jeffay, K.M. Crofton, W.R. Setzer, R.L. Cooper, T.E. Stoker, The
632 Effects of Triclosan on Puberty and Thyroid Hormones in Male Wistar Rats, *Toxicol. Sci.* 107 (2009)
633 56–64. doi:10.1093/toxsci/kfn225.

634 [114] EFSA, European Food Safety Authority (EFSA) panel on contaminants in the food chain

(CONTAM): Scientific opinion on tetrabromobisphenol A (TBBPA) and its derivatives in food, 2011. doi:10.2903/j.efsa.2011.2477.

[115] L.T.M. Van der Ven, T. Van de Kuil, A. Verhoef, C.M. Verwer, H. Lilienthal, P.E.G. Leonards, U.M.D. Schauer, R.F. Cantón, S. Litens, F.H. De Jong, T.J. Visser, W. Dekant, N. Stern, H. Håkansson, W. Slob, M. Van den Berg, J.G. Vos, A.H. Piersma, Endocrine effects of tetrabromobisphenol-A (TBBPA) in Wistar rats as tested in a one-generation reproduction study and a subacute toxicity study, *Toxicology*. 245 (2008) 76–89. doi:10.1016/j.tox.2007.12.009.

[116] Y. Cai, W. Zhang, J. Hu, G. Sheng, D. Chen, J. Fu, Characterization of maternal transfer of decabromodiphenyl ether (BDE-209) administered to pregnant Sprague–Dawley rats, *Reprod. Toxicol.* 31 (2011) 106–110. doi:10.1016/j.reprotox.2010.08.005.

[117] EFSA, Scientific Opinion on Polybrominated Diphenyl Ethers (PBDEs) in Food, 2011. doi:10.2903/j.efsa.2011.2156.

[118] D.C. Rice, E.A. Reeve, A. Herlihy, R. Thomas Zoeller, W. Douglas Thompson, V.P. Markowski, Developmental delays and locomotor activity in the C57BL6/J mouse following neonatal exposure to the fully-brominated PBDE, decabromodiphenyl ether, *Neurotoxicol. Teratol.* 29 (2007) 511–520. doi:10.1016/j.ntt.2007.03.061.

[119] L.T.M. van der Ven, A. Verhoef, T. van de Kuil, W. Slob, P.E.G. Leonards, T.J. Visser, T. Hamers, M. Herlin, H. Håkansson, H. Olausson, A.H. Piersma, J.G. Vos, A 28-Day Oral Dose Toxicity Study Enhanced to Detect Endocrine Effects of Hexabromocyclododecane in Wistar Rats, *Toxicol. Sci.* 94 (2006) 281–292. doi:10.1093/toxsci/kfl113.

[120] D.T. Szabo, J.J. Diliberto, H. Hakk, J.K. Huwe, L.S. Birnbaum, Toxicokinetics of the Flame Retardant Hexabromocyclododecane Alpha: Effect of Dose, Timing, Route, Repeated Exposure, and Metabolism, *Toxicol. Sci.* 121 (2011) 234–244. doi:10.1093/toxsci/kfr059.